非荷尔蒙避孕药市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球非荷尔蒙避孕药市场规模达199亿美元，预计到2034年将以7%的复合年增长率成长至391亿美元。民众对安全性行为的认识不断提高，加上政府的支持性措施以及消费者明显转向无荷尔蒙避孕方案，这些因素持续推动市场扩张。越来越多的消费者正在寻求能够避免荷尔蒙避孕方法常见副作用的避孕方法。

人们对避孕套等便捷易用的避孕用品日益增长的偏好，对市场动态产生了积极影响。由于价格实惠、供应充足，以及能够有效预防怀孕和性传染病，发展中地区男性对保险套的需求强劲。由于情绪波动和体重增加等副作用，许多使用者正在逐渐放弃荷尔蒙避孕产品，这促使人们对更安全的替代品的需求日益增长。此外，透过多种零售和数位管道广泛提供产品，也提升了消费者的可近性。产品可透过线上平台、连锁药局和附近的零售店便捷购买，从而鼓励消费者持续使用。这些因素预计将在未来几年保持成长势头。

预计器械细分市场将达到7.2%的复合年增长率，到2034年达到294亿美元。此细分市场的主要产品包括子宫内避孕器 (IUD)、皮下植入物、阴道环和保险套。其中，铜子宫内避孕器因其有效性和无激素特性而广受欢迎。保险套因其可及性和额外的抗感染保护作用，仍然是必不可少的避孕方法，使其成为非荷尔蒙避孕领域的主导产品。

2024年，女性用户群规模达126亿美元。女性持续选择非荷尔蒙避孕方案，包括长效可逆避孕药 (LARC)、杀精产品、植入物以及输卵管切除术等外科手术。选择通常受便利性、健康因素和长期可靠性的影响。输卵管结扎术是一种永久性绝育手术，涉及输卵管闭合，是40岁以上接近更年期的女性寻求可靠避孕方法的常见选择。可支配收入的增加、女性就业率的提高以及生殖健康意识的增强，也促进了非荷尔蒙避孕方案的采用率。

2024年，美国非荷尔蒙避孕药市场规模达58亿美元。患有多囊性卵巢综合症或甲状腺疾病等荷尔蒙疾病的患者通常依赖非荷尔蒙避孕药。不同的文化和法律对堕胎的限制进一步推动了市场的成长，促使人们更多地使用避孕措施。绝育技术的进步，包括针对男性和女性的微创技术，正在改善患者的体验和接受度。此外，业内人士正致力于开发下一代男性避孕解决方案，包括基于注射水凝胶的避孕方法，预计这将推动未来的需求成长。

全球非荷尔蒙避孕药市场的主要公司包括：拜耳、利洁时、迈耶、HLL Lifecare、PREGNA INTERNATIONAL、富士乳胶、Mankind、CooperCompanies、Church & Dwight Co.、SMB、CUPID、冈本、abbVie 和 VIATRIS。为了巩固其在非荷尔蒙避孕药领域的立足点，领先的公司优先考虑产品设计创新、拓展分销管道并开展有针对性的宣传活动。许多公司正在开发先进的屏障装置和消毒工具，以提供更舒适、更有效率和更便利的使用体验。公司投资于以使用者为中心的教育，以打破文化禁忌并促进知情选择。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 人们对荷尔蒙避孕药副作用的担忧日益增加
    • 计划延后怀孕的倾向日益增强
    • 发展中经济体未满足的避孕需求很高
    • 性传染病（STD）的盛行率不断上升
    • 政府措施提高民众对男性绝育的认识
  • 产业陷阱与挑战
    • 替代方法的可用性
    • 输精管切除手术相关风险
• 成长潜力分析
• 监管格局
• 创新与永续性
  • 非荷尔蒙避孕技术创新
  • 永续发展措施与环保产品
• 报销场景
• 差距分析
• 定价分析
• 保险套和子宫内避孕器－2024年全球和区域销售分析
• 设备分销前景
• 消费者行为分析
• 波特的分析
• PESTEL分析
• 价值链分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 装置
  • 保险套
    • 男性
    • 女性
  • 子宫内避孕器
  • 阴道环
  • 皮下植入物
  • 其他设备
• 消毒
  • 输精管切除术
    • 无刀输精管切除术
    • 传统输精管切除术
    • 微创输精管切除术
  • 输卵管结扎
    • 腹腔镜输卵管结扎术
    • 子宫腔镜输卵管结扎术
    • 小切口开腹手术
    • 其他程式
• 其他产品类型

第六章：市场估计与预测：依性别，2021 - 2034 年

• 主要趋势
• 男性
• 女性

第七章：市场估计与预测：按年龄组，2021 - 2034 年

• 主要趋势
• 15-44岁
• 44岁以上

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• abbVie
• Bayer
• Church & Dwight Co.
• CooperCompanies
• CUPID
• FUJI LATEX
• HLL Lifecare
• Mankind
• MAYER
• VIATRIS
• Okamoto
• PREGNA INTERNATIONAL
• reckitt
• SMB
• veru

The Global Non-Hormonal Contraceptives Market was valued at USD 19.9 billion in 2024 and is estimated to grow at a CAGR of 7% to reach USD 39.1 billion by 2034. Rising public awareness around safe sexual practices, combined with supportive government initiatives and a noticeable shift toward hormone-free contraceptive solutions, continues to drive market expansion. A growing number of consumers are seeking birth control options that avoid the side effects commonly linked with hormonal methods.

An increasing preference for accessible and easy-to-use contraceptives like condoms has positively impacted market dynamics. The market had a strong uptake among men in developing regions due to affordability, availability, and dual protection against pregnancy and STDs. Many users are moving away from hormone-based options due to side effects such as mood fluctuations and weight gain, contributing to the growing demand for safer alternatives. Additionally, wide product availability through multiple retail and digital channels enhances consumer access. Products are conveniently offered via online platforms, drugstore chains, and nearby retail outlets, encouraging consistent adoption. These factors are collectively expected to sustain growth in the coming years.

The devices segment is projected to achieve a CAGR of 7.2%, reaching USD 29.4 billion by 2034. Key products in this segment include intrauterine devices (IUDs), subdermal implants, vaginal rings, and condoms. Among these, copper IUDs have become widely preferred due to their effectiveness and hormone-free nature. Condoms remain an essential method due to their accessibility and added protection against infections, making them a dominant player in the non-hormonal contraceptives space.

In 2024, the female user segment accounted for USD 12.6 billion. Women continue to opt for non-hormonal solutions including long-acting reversible contraceptives (LARCs), spermicidal products, implants, and surgical procedures like tubectomy. Choices are often influenced by convenience, health factors, and long-term reliability. Tubal ligation, a permanent sterilization procedure involving the closure of fallopian tubes, is commonly selected by women over 40 who seek a dependable birth control method as they approach menopause. Rising disposable income, increased participation of women in the workforce, and greater reproductive health awareness are also contributing to higher adoption.

U.S. Non-Hormonal Contraceptives Market was valued at USD 5.8 billion in 2024. Individuals managing hormonal conditions such as polycystic ovary syndrome or thyroid disorders often rely on non-hormonal options. Market growth is further supported by varying cultural and legal restrictions on abortion, prompting greater use of contraception. Technological advances in sterilization, including minimally invasive options for both men and women, are improving patient experience and acceptance. Additionally, industry players are focusing on developing next-generation solutions for male contraception, including injectable hydrogel-based methods, which is expected to boost future demand.

Key companies in the Global Non-Hormonal Contraceptives Market include: Bayer, Reckitt, MAYER, HLL Lifecare, PREGNA INTERNATIONAL, FUJI LATEX, Mankind, CooperCompanies, Church & Dwight Co., SMB, CUPID, Okamoto, abbVie, and VIATRIS. To strengthen their foothold in the non-hormonal contraceptives sector, leading companies prioritize innovation in product design, expand distribution channels, and launch targeted awareness campaigns. Many are developing advanced barrier devices and sterilization tools that offer greater comfort, efficiency, and accessibility. Companies invest in user-centric education to break cultural taboos and promote informed choices.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising concerns over side effects of hormonal contraceptives
    • 3.2.1.2 Growing inclination towards planned delayed pregnancy
    • 3.2.1.3 High unmet contraceptive needs in developing economies
    • 3.2.1.4 Growing prevalence of sexually transmitted diseases (STD)
    • 3.2.1.5 Government initiatives raising awareness about male sterilization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative methods
    • 3.2.2.2 Risk associated with vasectomy surgeries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Innovation and sustainability
  • 3.5.1 Technological innovations in non-hormonal contraceptives
  • 3.5.2 Sustainability initiatives and eco-friendly products
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Pricing analysis
• 3.9 Condoms and IUDs - global and regional volume analysis, 2024
• 3.10 Distribution outlook for devices
• 3.11 Consumer behavior analysis
• 3.12 Porter's analysis
• 3.13 PESTEL analysis
• 3.14 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Condoms
    • 5.2.1.1 Male
    • 5.2.1.2 Female
  • 5.2.2 Intra-uterine devices
  • 5.2.3 Vaginal rings
  • 5.2.4 Subdermal implants
  • 5.2.5 Other devices
• 5.3 Sterilization
  • 5.3.1 Vasectomy
    • 5.3.1.1 No-scalpel vasectomy
    • 5.3.1.2 Conventional vasectomy
    • 5.3.1.3 Minimally invasive vasectomy
  • 5.3.2 Tubal ligation
    • 5.3.2.1 Laparoscopic tubal ligation
    • 5.3.2.2 Hysteroscopic tubal ligation
    • 5.3.2.3 Mini-Laparotomy
    • 5.3.2.4 Other procedures
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 15-44 years
• 7.3 Above 44 years

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 abbVie
• 9.2 Bayer
• 9.3 Church & Dwight Co.
• 9.4 CooperCompanies
• 9.5 CUPID
• 9.6 FUJI LATEX
• 9.7 HLL Lifecare
• 9.8 Mankind
• 9.9 MAYER
• 9.10 VIATRIS
• 9.11 Okamoto
• 9.12 PREGNA INTERNATIONAL
• 9.13 reckitt
• 9.14 SMB
• 9.15 veru